Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

A Phase 1b/2 Study of Prolonged Infusion Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: Updated Efficacy and Tolerability from the Completed 20/56 mg/m(2) Expansion Cohort of PX-171-007
The Phase 1b/2 study evaluated the safety and efficacy of a prolonged, 30-minute infusion of carfilzomib at a dose of 56mg/m(2) in 24 patients who previously had received a median of 4.5 lines of therapy. Authors observed a 60 percent ORR and an acceptable safety profile at this dose in these heavily pretreated patients.  These results support preclinical findings that longer infusion times enable higher doses and achieve greater levels of proteasome inhibition.

Abstract #3969: The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results from Two Multicenter Phase 2 Clinical Trials
An analysis of two Phase 2 studies demonstrated that the speed of response to carfilzomib was rapid. Rapid response was defined as achievement of minimal response or better within a median of 0.5 to 1.0 months. When results were analyzed according to baseline characteristics, there was a trend of longer times to clinical benefit response in patients with a greater number of prior therapeutic regimens.

About the Phase 2 Studies

  • The 004 study, an open-label, single-agent Phase 2 study of carfilzomib, was conducted in collaboration with the Multiple Myeloma Research Consortium (MMRC) and other institutions, and enrolled 129 patients with relapsed and/or refractory multiple myeloma who had received one to three prior treatments. Patients were divided into two populations: bortezomib-naive patients and patients previously treated with bortezomib. Prior therapies included alkylating agents, stem cell transplant, thalidomide, lenalidomide and anthracyclines, and bortezomib in the bortezomib-t
    '/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... July 30, 2015 Tianyin Pharmaceutical Inc. (NYSE ... that specializes in the patented biopharmaceutical, modernized traditional Chinese ... provided updates regarding the notice it received on May ... indicating that the Company was below certain of the ... 134 and 1101 of the NYSE MKT Company Guide, ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... Given the narrow initial public offering window, declining venture ... become the exit of choice for many biopharmaceutical companies. In ... was higher, but it still wasn,t the flood of deals ... Another not-so-positive trend for biotech in 2011 was ...
... Independa™ announced today that it has closed ... that surpassed the target of $2.2 million indicating strong ... solutions that enhance independence for older adults. ... top of $1.6 million in seed-round venture capital funding ...
Cached Medicine Technology:Biopharma M&A Trends Hold Steady, But Deals Declined in 2011 2Independa Closes Convertible Note Funding at $2.35 Million 2Independa Closes Convertible Note Funding at $2.35 Million 3
(Date:7/31/2015)... ... 31, 2015 , ... Recently touted by Becker’s Healthcare as ... analytics , Jvion continues to disrupt the predictive analytic and big data market ... and population level illness to drive prevention and better health outcomes. Most recently, ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator ... new applicator in the United States as an upgrade to the CoolSmooth applicator cleared ... applicator required a 2 hour treatment time. The new CoolSmooth Pro reduces the ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Group, Inc. has re-branded their social media profiles to better connect with the ... consumers to communicate, find information, share insights and opinions. The Rally Insurance Group, ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... Rodgers Theatre . Those looking to catch a new and refreshing show on ... won numerous awards and achievements including an Obie Award, Outer Critics Circle Award, Drama ...
(Date:7/31/2015)... Las Vegas, NV (PRWEB) , ... July 31, 2015 , ... ... Vegas bakery is now offering wedding cakes with custom designs, making life ... hard to deliver beautifully designed wedding cakes for each customer who orders one. , ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 2Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 3Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 4Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 5Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 6Health News:Cheap Hamilton Tickets at Richard Rodgers Theatre: Ticket Down Slashes Ticket Prices for Hamilton in New York City at the Richard Rodgers Theatre 7Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... has found the first reliable evidence that early detection of ... disease can halve the women,s chances of death from breast ... 18 March) in the cancer journal, Annals of Oncology ... at its early, asymptomatic stage, then the women,s chances of ...
... The Generic Pharmaceutical Association (GPhA) released the following ... regarding the introduction of H.R. 1548, "The Pathway for ... the wrong road for patients looking for safe and ... It is a long route filled with needless ...
... nail pain, too, , , TUESDAY, March 17 (HealthDay News) -- ... seems to help reduce nail psoriasis, according to Italian researchers. ... have nail psoriasis, which includes irregular pitting, salmon-colored patches on ... bed and reddened and often inflamed borders on the nails. ...
... WOODLANDS, Texas, March 17 Standard & Poor,s Rating ... rating to ,B, on Huntsman Corporation,s (NYSE: ... Huntsman reaffirms that its operations are sound and that ... economic recession. Huntsman has met the challenging operating ...
... at the Whitehead Institute for Biomedical Research and the ... (miRNA) capable of directly tamping down the activity of ... to prevent tumor formation, the p53 gene is thought ... , RELEVANCE: The study reports the first time a ...
... of Dental and Craniofacial Research (NIDCR) awarded the American ... Grant in the amount of $250,000, which will fund ... assist approximately 50 students and NIDCR-supported trainees in attending ... & Exhibition for the next five years in the ...
Cached Medicine News:Health News:Early detection of second breast cancers halves women's risk of death 2Health News:Early detection of second breast cancers halves women's risk of death 3Health News:Early detection of second breast cancers halves women's risk of death 4Health News:GPhA Statement on Introduction of H.R. 1548, 'The Pathway for Biosimilars Act' 2Health News:Low-Dose Acitretin May Reduce Nail Psoriasis 2Health News:Huntsman Responds to S&P Action 2Health News:Huntsman Responds to S&P Action 3Health News:MicroRNA undermines tumor suppression 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: